(Q42938838)

11 November 2017

title

Combination intravitreal rituximab and methotrexate for massive subretinal lymphoma (English)

1 reference

11 November 2017

1 reference

1 reference

S Yeh

1

1 reference

11 November 2017

D J Wilson

series ordinal

2

1 reference

11 November 2017

publication date

13 August 2010

1 reference

11 November 2017

1 reference

11 November 2017

volume

24

1 reference

11 November 2017

issue

10

1 reference

11 November 2017

page(s)

1625-1627

1 reference

https://scigraph.springernature.com/pub.10.1038/eye.2010.111

11 November 2017

exact match

0 references

cites work

Intraocular lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.111

International Central Nervous System and Ocular Lymphoma Workshop: recommendations for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.111

Effect of intravitreous rituximab injections in patients with recurrent ocular lesions associated with central nervous system lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.111

Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.111

Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.111

inferred from DOI database lookup

7 January 2021

based on heuristic

Intraocular use of rituximab

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.111

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/EYE.2010.111

1 reference

Dimensions Publication ID

11 November 2017

1045803275

0 references

1 reference